DE60207277D1 - Bakterieller impfstoff - Google Patents

Bakterieller impfstoff

Info

Publication number
DE60207277D1
DE60207277D1 DE60207277T DE60207277T DE60207277D1 DE 60207277 D1 DE60207277 D1 DE 60207277D1 DE 60207277 T DE60207277 T DE 60207277T DE 60207277 T DE60207277 T DE 60207277T DE 60207277 D1 DE60207277 D1 DE 60207277D1
Authority
DE
Germany
Prior art keywords
attenuated
bacteria
enterotoxins
bacterial vaccine
provides strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60207277T
Other languages
English (en)
Other versions
DE60207277T2 (de
Inventor
Arthur Keith Turner
Judith Greenwood
Jonathan Clive Stephens
Juliet Claire Beavis
Michael James Darsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Acambis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60207277(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Research Ltd filed Critical Acambis Research Ltd
Application granted granted Critical
Publication of DE60207277D1 publication Critical patent/DE60207277D1/de
Publication of DE60207277T2 publication Critical patent/DE60207277T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60207277T 2001-09-11 2002-09-11 Bakterieller impfstoff Revoked DE60207277T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121998 2001-09-11
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines
PCT/GB2002/004123 WO2003022306A2 (en) 2001-09-11 2002-09-11 Bacterial vaccine

Publications (2)

Publication Number Publication Date
DE60207277D1 true DE60207277D1 (de) 2005-12-15
DE60207277T2 DE60207277T2 (de) 2006-08-03

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60207277T Revoked DE60207277T2 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff
DE60207278T Expired - Lifetime DE60207278T3 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60207278T Expired - Lifetime DE60207278T3 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff

Country Status (10)

Country Link
US (4) US7943122B2 (de)
EP (2) EP1425037B1 (de)
AT (2) ATE308991T1 (de)
AU (2) AU2002321644B2 (de)
CA (2) CA2459586A1 (de)
DE (2) DE60207277T2 (de)
DK (2) DK1425037T3 (de)
ES (2) ES2256515T5 (de)
GB (1) GB0121998D0 (de)
WO (2) WO2003022306A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7468269B2 (en) * 2003-02-26 2008-12-23 University Of Massachusetts Reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
WO2005113827A2 (en) * 2004-05-19 2005-12-01 THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE ARMY, Walter REED ARMY INSTITUTE OF RESEARCH Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e. coli
EP1855718B1 (de) 2005-01-11 2016-10-12 The United States of America as represented by The Secretary of The Navy Donor Strang komplementierte Adhesine als immunogen gegen Escherichia coli.
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
KR20100040847A (ko) * 2007-07-02 2010-04-21 크루셀 스웨덴 아베 장독소생산 Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉ 세균의 콜로니화 인자(ＣＦ) 항원의 발현을 위한 혼성 오페론
US9410157B2 (en) * 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
WO2013037718A1 (en) 2011-09-12 2013-03-21 Scandinavian Biopharma Holding Ab Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof
WO2014047625A1 (en) 2012-09-24 2014-03-27 Montana State University Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
EP2920203B1 (de) 2012-11-19 2019-06-05 The United States of America as represented by the Secretary of the Navy Rekombinantes polypeptidkonstrukt mit mehreren enterotoxigenen escherichia coli-fimbrienuntereinheiten
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
JP2017537145A (ja) 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ カンピロバクター・ジェジュニに対する合成抗原コンストラクト
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
EP3773700A4 (de) * 2018-04-03 2022-01-05 University of Maryland, Baltimore Verbesserter multivalenter impfstoff gegen shigella-enterotoxigene e. coli

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
ES2131069T3 (es) 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
EP1216303A1 (de) * 1999-09-15 2002-06-26 Mogam Biotechnology Research Institute Detoxifizierte mutanten des hitze-labilen enterotoxins aus escherichia coli
US6902736B2 (en) * 2000-04-20 2005-06-07 University Of Maryland, Baltimore Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2010048322A1 (en) * 2008-10-21 2010-04-29 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US9327019B2 (en) * 2009-06-30 2016-05-03 Stc.Unm Attenuated enterohemorrhagic E. coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
EP1425038B1 (de) 2005-11-09
CA2460025A1 (en) 2003-03-20
US20110200638A1 (en) 2011-08-18
EP1425038B2 (de) 2010-09-01
WO2003022306A2 (en) 2003-03-20
DE60207278D1 (de) 2005-12-15
ES2256515T3 (es) 2006-07-16
DE60207277T2 (de) 2006-08-03
EP1425037B1 (de) 2005-11-09
US20110189225A1 (en) 2011-08-04
DE60207278T3 (de) 2011-05-05
ATE308992T1 (de) 2005-11-15
ES2256514T3 (es) 2006-07-16
EP1425037A2 (de) 2004-06-09
GB0121998D0 (en) 2001-10-31
ES2256515T5 (es) 2011-02-25
ATE308991T1 (de) 2005-11-15
US7943122B2 (en) 2011-05-17
WO2003022307A1 (en) 2003-03-20
US8318148B2 (en) 2012-11-27
DK1425037T3 (da) 2006-03-27
CA2459586A1 (en) 2003-03-20
EP1425038A1 (de) 2004-06-09
US20040253710A1 (en) 2004-12-16
US7951361B2 (en) 2011-05-31
AU2002321644B2 (en) 2008-03-13
DK1425038T4 (da) 2010-12-13
DK1425038T3 (da) 2006-03-27
WO2003022306A3 (en) 2003-06-26
AU2002321652B2 (en) 2008-04-10
DE60207278T2 (de) 2006-08-10
US20050054075A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
DK1425037T3 (da) Bakteriel vaccine
WO2002053189A3 (en) Immunogenic complex
ATE357249T1 (de) Auf bläschen basierendes impfstoff gegen chlamydia
MX339524B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUP0203056A1 (hu) Vakcinakészítmény
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
WO2006123155A3 (en) Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
WO2000037609A3 (en) Orally immunogenic bacterial enterotoxins expressed in transgenic plants
WO2002034773A3 (en) Streptococcal genes
HU0005010D0 (de)
ATE413888T1 (de) Salmonella vakzine
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
EP1908839A3 (de) Virulenzgene, Proteine und ihre Anwendung
ATE359815T1 (de) Streptococcus-phocae-vakzine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
EP1430025A4 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
DK1660121T3 (da) Levende svækket bakteriel vaccine
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
EP1803807A3 (de) Virulenz gene, proteine, und ihre verwendung
RU2001132094A (ru) Штамм бактерий Escherichia coli № 28 09:K99, используемый для изготовления вакцин и диагностических препаратов
RU99117155A (ru) Штамм бактерий pseudomonas aeruginosa 5292, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU99117152A (ru) Штамм бактерий pseudomonas aeruginosa 4492, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU2003110247A (ru) Штамм escherichia coli б-5, используемый для получения термолабильного экзотоксина

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation